Vertex Pharmaceuticals Incorporated (VRTX) has announced its plans to acquire Alpine Immune Sciences, Inc. (ALPN), a company dedicated to the discovery and development of novel protein-based immunotherapies. The acquisition, valued at approximately $4.9 billion, will see Vertex purchasing Alpine at $65 per share in an all-cash transaction. The strategic acquisition has received unanimous support from…
All posts tagged Vertex pharmaceuticals
LCT to benefit from Semma Therapeutics acquisition by Vertex
AUCKLAND: Living Cells Technologies (LCT) holds 121,995 shares in Semma Therapeutics, worth an anticipated USD 838,105 which would be realised on Vertex Pharmaceuticals Incorporated completing its acquisition of Semma Therapeutics. The acquisition is anticipated to close in the fourth quarter of 2019, subject to certain conditions. Semma Therapeutics, a privately held biotechnology company pioneering the…